(Q38289734)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

review article

1 reference

title

Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

4

Stanislas Pol

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Marie-Louise Michel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Hélène Fontaine

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

16 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

Medical Microbiology and Immunology

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

204

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

121-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00430-014-0381-y

25 February 2020

exact match

0 references

cites work

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Hepatitis B Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Noncytolytic control of viral infections by the innate and adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

The molecular basis of the failed immune response in chronic HBV: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Therapeutic vaccination in chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

High antigen levels are the cause of T cell exhaustion during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Antiviral T-cell responses and therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

DNA vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Increase of Plasma IL-12/p40 Ratio Induced by the Combined Therapy of DNA Vaccine and Lamivudine Correlates with Sustained Viremia Control in CHB Carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Vaccines and immunotherapies against hepatitis B and hepatitis C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-014-0381-Y

Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections

21 January 2018

1 reference

12 December 2020

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

1 reference

12 December 2020

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

12 December 2020

Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice

1 reference

12 December 2020

GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees

1 reference

12 December 2020

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

1 reference

12 December 2020

A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy

1 reference

12 December 2020

Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization

1 reference

12 December 2020

Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model

1 reference

12 December 2020

Specific vaccine therapy in chronic hepatitis B infection

1 reference

12 December 2020

Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice

1 reference

12 December 2020

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

12 December 2020

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

1 reference

12 December 2020

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

12 December 2020

10.1007/S00430-014-0381-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

25 February 2020

1016810024

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25511871%20AND%20SRC:MED&resulttype=core&format=json